Increased serum ferritin concentrations and liver enzyme activities in patients with metabolic syndrome

Metabolic Syndrome and Related Disorders

Volumn 4, Issue 3, 2006, Pages 196-203

  Tsimihodimos, Vasilis ^a   Gazi, Irene ^a   Kalaitzidis, Rigas ^a   Elisaf, Moses ^a   Siamopoulos, Kostantinos C ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; INSULIN; LIVER ENZYME;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANALYSIS OF COVARIANCE; ANALYSIS OF VARIANCE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ENZYME ACTIVITY; FATTY LIVER; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; IRON BLOOD LEVEL; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIPLE REGRESSION; PATHOGENESIS; PRIORITY JOURNAL;

EID: 33750310164     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2006.4.196     Document Type: Article

References (31)

1. Witte DL, Crosby WH, Edwards CQ, et al. Practice guideline development task force of the College of American Pathologists. Hereditary hemochromatosis. Clin Chim Acta 1996;245:139-200.
2. Ford ES, Cogswell ME. Diabetes and serum ferritin concentration among U.S. adults. Diabetes Care 1999; 22:1978-1983.
3. Jiang R, Manson JE, Meigs JB, et al. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA 2004;291:711-717.
4. Tuomainen TP, Nyyssonen K, Salonen R, et al. Body iron stores are associated with serum insulin and blood glucose concentrations. Population study in 1,013 eastern Finnish men. Diabetes Care 1997;20:426-428.
5. Awai M, Narasaki M, Yamanoi Y, et al. Induction of diabetes in animals by parenteral administration of ferric nitrilotriacetate. A model of experimental hemochromatosis. Am J Pathol 1979;95:663-673.
6. Borel MJ, Beard JL, Farrell PA. Hepatic glucose production and insulin sensitivity and responsiveness in iron-deficient anemic rats. Am J Physiol 1993;264: E380-E390.
7. Sulieman M, Asleh R, Cabantchik ZI, et al. Serum chelatable redox-active iron is an independent predictor of mortality after myocardial infarction in individuals with diabetes. Diabetes Care 2004;27:2730-2732.
8. Fernandez-Real JM, Lopez-Bermejo A, Ricart W. Cross-talk between iron metabolism and diabetes. Diabetes 2002;51:2348-2354.
9. National Institutes of Health. Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Bethesda, MD: National Institutes of Health, 2001.
10. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-1428.
11. Jehn M, Clark JM, Guallar E. Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 2004;27:2422-2428.
12. Fernandez-Real JM, Ricart-Engel W, Arroyo E, et al. Serum ferritin as a component of the insulin resistance syndrome. Diabetes Care 1998;21:62-68.
13. Eshed I, Elis A, Lishner M. Plasma ferritin and type 2 diabetes mellitus: a critical review. Endocrinol Res 2001;27:91-97.
14. Dinneen SF, Silverberg JD, Batts KP, et al. Liver iron stores in patients with non-insulin-dependent diabetes mellitus. Mayo Clin Proc 1994;69:13-15.
15. Marchesini G, Marzocchi R, Agostini F, et al. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 2005;16:421-427.
16. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-923.
17. Bugianesi E, Manzini P, D'Antico S, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004;39:179-187.
18. Chitturi S, Weltman M, Farrell GC, et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 2002;36:142-149.
19. Hsiao TJ, Chen JC, Wang JD. Insulin resistance and ferritin as major determinants of nonalcoholic fatty liver disease in apparently healthy obese patients. Int J Obes Relat Metab Disord 2004;28:167-172.
20. Fargion S, Mattioli M, Fracanzani AL, et al. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96:2448-2455.
21. Tsimihodimos V, Kostoula A, Kakafika A, et al. Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values. J Cardiovasc Pharmacol Ther 2004;9:27-33.
22. Oberkanins C, Moritz A, de Villiers JN, et al. A reverse-hybridization assay for the rapid and simultaneous detection of nine HFE gene mutations. Genet Test 2000;4:121-124.
23. Angelico F, Del Ben M, Conti R, et al. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab-2005;90:1578-1582.
24. alpha' Med Hypotheses 2003;61:567-573.
25. Fernandez-Real JM, Penarroja G, Castro A, et al. Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and beta-cell function. Diabetes 2002;51:1000-1004.
26. Facchini FS. Effect of phlebotomy on plasma glucose and insulin concentrations. Diabetes Care 1998;21:2190.
27. Cutler P. Deferoxamine therapy in high-ferritin diabetes. Diabetes 1989;38:1207-1210.
28. Zacharski LR, Ornstein DL, Woloshin S, et al. Association of age, sex, and race with body iron stores in adults: analysis of NHANES III data. Am Heart J 2000;140:98-104.
29. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 2003;107:391-397.
30. Lee DH, Steffen LM, Jacobs DR Jr. Association between serum gamma-glutamyltransferase and dietary factors: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Am J Clin Nutr 2004;79:600-605.
31. Ruttmann E, Brant LJ, Concin H, et al. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation 2005;112:2130-2137.